NASDAQ · LIXT
Lixte Biotechnology Holdings, Inc.
$7.21-$0.46 (-6.0%)
Lixte Biotechnology Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.96% below the high.
Loading market information…
NASDAQ · CDT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CDT Equity Inc.’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow CDT Equity Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:07 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.21-$0.46 (-6.0%)
Lixte Biotechnology Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.96% below the high.
$6.50-$0.16 (-2.4%)
Envoy Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.87% below the high.
$1.82-$0.09 (-4.71%)
SCWorx Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.46% below the high.
$1.46-$0.01 (-0.68%)
Enveric Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.98% below the high.
$0.14-$0.01 (-6.67%)
Hepion Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.36% below the high.
$1.14-$0.06 (-5.0%)
NewGenIvf Group Limited’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
$3.66-$0.19 (-4.94%)
Concord Medical Services Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 46.18% below the high.
$0.11$0.00 (0.0%)
Longevity Health Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.41% below the high.
